Skip to main content
TipRanks
Go Ultimate75% OFF

Jazz Pharmaceuticals (J7Z) Stock Price & Analysis

0 Followers

J7Z Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 12.76B
Enterprise Value
CHF 17.77B
Total Cash (Recent Filing)
CHF 2.86B
Total Debt (Recent Filing)
CHF 5.64B
Price to Earnings (P/E)
64.3
Beta
0.34
Next Earnings
Mar 02, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Cash Generation

Robust operating and free cash flow gives Jazz internal funding capacity for product launches, pipeline development, acquisitions and debt management. Because cash generation has generally tracked reported earnings, it also supports the quality and durability of the company’s operating model.

High-margin Growth Platform

Raised revenue guidance alongside very high gross-margin expectations indicates that Jazz is expanding while retaining substantial economics on product sales. This supports reinvestment in commercial execution and research, and provides operating leverage as newer therapies scale.

Product And Pipeline Expansion

Jazz is strengthening its long-term portfolio through an oncology launch with meaningful clinical differentiation and a rare-epilepsy pipeline addition. These assets broaden therapeutic exposure beyond existing products and create opportunities for future growth in specialized markets.

Bears Say

Elevated Leverage

Elevated debt reduces financial flexibility even though leverage has improved from 2022 levels. Interest obligations and refinancing needs can constrain investment choices, particularly if product growth slows or Jazz must fund additional acquisitions and development programs.

Earnings And Margin Volatility

Strong gross margins have not translated into consistently stable earnings, with profitability moving from solid results to a loss and then only a modest recovery. Royalty costs, technology transfers and rising investment spending may continue to pressure earnings conversion.

Zepzelca Competitive Pressure

Expected competition in first-line maintenance small-cell lung cancer creates a structural risk to Zepzelca’s future contribution. If the competing therapy gains approval and reimbursement, Jazz may face weaker demand, reduced market share or greater commercial spending.

Jazz Pharmaceuticals News

J7Z FAQ

What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is CHF12.76B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 101 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Nov 02, 2026. The company reported -CHF3.273 earnings per share for the quarter, beating the consensus estimate of -CHF3.403 by CHF0.129.
Is Jazz Pharmaceuticals overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 5.87.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 64,189,050 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of -CHF3.273 in its last earnings report, beating expectations of -CHF3.403. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Hedge funds hold Jazz Pharmaceuticals shares: the largest hedge-fund position in Jazz Pharmaceuticals is 330,648,741 shares, and hedge funds decreased their holdings by 228.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology